Tsong Yi, Zhong Jinglin
DBVI, Office of Biostatistics, Office of Translational Science, Center for Drug Evaluation and Research, Food and Drug Adminisration, Silver Spring, Maryland, USA.
J Biopharm Stat. 2010 May;20(3):604-14. doi: 10.1080/10543400903582034.
The primary objective of a thorough QT clinical trial is to demonstrate the lack of QT prolongation induced by the test treatment. The ICH E14 guidance defined drug-induced prolongation of QT interval as evidenced by an upper bound of the 95% one-sided confidence interval around the mean effect on QTc of 10 ms. Furthermore, it defined a negative thorough QT/QTc study as one in which the upper bound of the 95% one-sided confidence interval for the largest time-matched mean effect of the drug on the QTc interval excludes 10 ms. Conventionally, this objective is tested with the intersection-union test by testing the mean difference between the test treatment and placebo of QTc changes from baseline at each of the matched time points. The multiple-comparison nature of the test leads to higher false positive rate when comparisons are made repeatedly at multiple time points. Many approaches have been proposed in the last 5 years in order to improve the efficiency of the test. In this article, we survey and discuss some of the approaches.
一项全面的QT临床试验的主要目标是证明受试治疗不会导致QT间期延长。国际人用药品注册技术协调会(ICH)E14指南将药物引起的QT间期延长定义为,围绕药物对QTc平均效应的95%单侧置信区间的上限证明QTc延长10毫秒。此外,该指南将一项阴性的全面QT/QTc研究定义为,药物对QTc间期的最大时间匹配平均效应的95%单侧置信区间的上限不包括10毫秒。传统上,通过在每个匹配时间点测试受试治疗与安慰剂之间QTc相对于基线变化的平均差异,采用交叉联合检验来检验这一目标。由于在多个时间点重复进行比较,该检验的多重比较性质导致假阳性率较高。在过去5年中,为了提高检验效率,人们提出了许多方法。在本文中,我们将对其中一些方法进行综述和讨论。